These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35287311)

  • 21. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
    Khiali S; Khani E; B Rouy S; Entezari-Maleki T
    Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19.
    Rasmussen HB; Hansen PR
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molnupiravir, an Oral Antiviral Treatment for COVID-19.
    Fischer W; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Loftis AJ; Alabanza P; Lipansky F; Painter WP
    medRxiv; 2021 Jun; ():. PubMed ID: 34159342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment.
    Githaka JM
    Bioinform Biol Insights; 2022; 16():11779322221085077. PubMed ID: 35342288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India.
    Sinha S; N K; Suram VK; Chary SS; Naik S; Singh VB; Jain MK; Suthar CP; Borthakur S; Sawardekar V; Sk N; Reddy N; Talluri L; Thakur P; Reddy M; Panapakam M; Vattipalli R
    Cureus; 2022 Nov; 14(11):e31508. PubMed ID: 36532902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19).
    Pagliano P; Sellitto C; Ascione T; Scarpati G; Folliero V; Piazza O; Franci G; Filippelli A; Conti V
    Expert Opin Drug Discov; 2022 Dec; 17(12):1299-1311. PubMed ID: 36508255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
    De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G
    J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
    Holman W; Holman W; McIntosh S; Painter W; Painter G; Bush J; Cohen O
    Trials; 2021 Aug; 22(1):561. PubMed ID: 34425873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.
    Schöning V; Kern C; Chaccour C; Hammann F
    Front Pharmacol; 2022; 13():816429. PubMed ID: 35222030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.
    Cheema HA; Abdul Rab S; Butt M; Jafar U; Shahid A; Rehman AU; Lee KY; Sahra S; Sah R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):396-402. PubMed ID: 38555274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
    Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns.
    Petit PR; Touret F; Driouich JS; Cochin M; Luciani L; Bernadin O; Laprie C; Piorkowski G; Fraisse L; Sjö P; Mowbray CE; Escudié F; Scandale I; Chatelain E; de Lamballerie X; Solas C; Nougairède A
    Heliyon; 2024 May; 10(10):e30862. PubMed ID: 38803975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir.
    Al-Taie A; Denkdemir FR; Sharief Z; Buyuk AS; Şardaş S
    OMICS; 2022 Jun; 26(6):324-328. PubMed ID: 35580151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study.
    Park HR; Yoo MG; Kim JM; Bae SJ; Lee H; Kim J
    Infect Chemother; 2023 Dec; 55(4):490-499. PubMed ID: 38014730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.
    Teli D; Balar P; Patel K; Sharma A; Chavda V; Vora L
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
    Wallace KB; Bjork JA
    Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.